Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
株式のランク #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
株価
$0.11725176
最終同期: 2025-07-14
時価総額
$481.50K
変化(1日)
-0.20%
変化(1年)
0.00%
FR
取引 PHAXIAM Therapeutics S.A. (PHXM)

カテゴリー

PHAXIAM Therapeutics S.A.(PHXM)の営業利益率
August 2026 時点の営業利益率 TTM: -1,784.31%
PHAXIAM Therapeutics S.A. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -1,784.31% です。2022 年末時点では -482.67% でした。
PHAXIAM Therapeutics S.A. の営業利益率の履歴(2016 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -1,784.31% 0.00%
2023 -1,784.31% 269.67%
2022 -482.67% -66.76%
2021 -1,452.03% -25.59%
2020 -1,951.32% 48.63%
2019 -1,312.83% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.97% -100.02%
US
28.81% -100.02%
NL
0.00% -
CH
0.00% -
KR
31.23% -100.02%
BE
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。